Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress, 2022, Ronghui Yang et al

Discussion in 'Other health news and research' started by Mij, Nov 20, 2022.

  1. Mij

    Mij Senior Member (Voting Rights)

    Messages:
    8,792
    Abstract
    An enhanced NADH/NAD+ ratio, termed reductive stress, is associated with many diseases. However, whether a downstream sensing pathway exists to mediate pathogenic outcomes remains unclear.

    Here, we generate a soluble pyridine nucleotide transhydrogenase from Escherichia coli (EcSTH), which can elevate the NADH/NAD+ ratio and meantime reduce the NADPH/NADP+ ratio. Additionally, we fuse EcSTH with previously described LbNOX (a water-forming NADH oxidase from Lactobacillus brevis) to resume the NADH/NAD+ ratio.

    With these tools and by using genome-wide CRISPR/Cas9 library screens and metabolic profiling in mammalian cells, we find that accumulated NADH deregulates PRPS2 (Ribose-phosphate pyrophosphokinase 2)-mediated downstream purine biosynthesis to provoke massive energy consumption, and therefore, the induction of energy stress. Blocking purine biosynthesis prevents NADH accumulation-associated cell death in vitro and tissue injury in vivo.

    These results underscore the pathophysiological role of deregulated purine biosynthesis in NADH accumulation-associated disorders and demonstrate the utility of EcSTH in manipulating NADH/NAD+ and NADPH/NADP+.

    Results
    Generation of tools for manipulation of cellular NADH/NAD+ and NADPH/NADP+
    Electrons in NADH and NADPH can be translocated or trans hydrogenated between each other6,14. Therefore, the couples of NADH/NAD+ and NADPH/NADP+ are tightly metabolically connected in cells (Fig. 1a). Upon reductive stress, the elevated NADH/NAD+ ratio can rewire cellular transformations to dissipate electrons mainly by promoting glutamine-initiated lipogenesis, thus it often leads to a concomitant decrease in the NADPH/NADP+ ratio6.

    Typically, hypoxia and ETC inhibition by antimycin A enhanced the cellular level of NADH and ratio of NADH/NAD+, concomitantly reducing the cellular level of NADPH and ratio of NADPH/NADP+ (Supplementary Fig. 1a, b). If we used α-ketobutyrate, a pyruvate analog that can be reduced to excretory α-hydroxybutyrate and thus reduce NADH accumulation8, to treat cells, it simultaneously restored the ratios of NADH/NAD+ and NADPH/NADP+ and cell proliferation under the conditions of hypoxia and ETC inhibition


    https://www.nature.com/articles/s41467-022-34850-0

     

Share This Page